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Background: The efficacy of highly active antiretroviral therapy (HAART) in the treatment of HIV infection is
influenced by factors such as potency of applied drugs, adherence of the patient, and resistance-associated
mutations. Up to now, there is insufficient data on the impact of the therapeutic setting.
Methods: Since 2001, the prospective multicenter RESINA study has examined the epidemiology of transmitted HIV
drug resistance in Nordrhein-Westfalen, the largest federal state of Germany by population. Characteristics of
patients treated in hospital-based outpatient units were compared to those of patients treated in medical practices.
Longitudinal data of all participants are being followed in a cohort study.
Results: Overall, 1,591 patients were enrolled between 2001 and 2009 with follow-up until the end of 2010. Of
these, 1,099 cases were treated in hospital-based units and 492 in private practices. Significant differences were
found with respect to baseline characteristics. A higher rate of patients with advanced disease and non-European
nationality were cared for in hospital units. Patients in medical practices were predominantly Caucasian men who
have sex with men (MSM) harboring HIV-1 subtype B, with lower CDC stage and higher CD4 cell count. Median viral
load was 68,828 c/mL in hospital-based units and 100,000 c/mL in private practices (P = 0.041). Only median age
and rate of transmitted drug resistance were not significantly different. After 48 weeks, 81.9% of patients in hospital
units and 85.9% in private practices had a viral load below the limit of detection (P = 0.12). A similar result was seen
after 96 weeks (P = 0.54). Although the baseline CD4 cell count was different (189.5/μL in hospital units and 246.5/
μL in private practices, P <0.001), a consistent and almost identical increase was determined in both groups.
Conclusions: The RESINA study covers a large HIV-infected patient cohort cared for in specialized facilities in
Germany. Despite significant differences of patients’ baseline characteristics in hospital-based units compared to
medical practices, we could not find significant differences in treatment outcome up to 2 years after the initiation
of HAART.
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Currently, there are approximately 78,000 HIV-infected
persons in Germany, and about 3,000 individuals are
newly infected each year. More than 50,000 patients re-
ceive highly active antiretroviral therapy (HAART) [1].
After more than a decade of widespread application of
HAART, the life expectancy of HIV-infected patients has
approached the level of the non-infected population [2].
In general, efficacy of first-line HAART exceeds 80%,
measured by the proportion of patients with a viral load
below the detection limit [3]. But even after repeated
treatment modifications including a variety of substance
combinations, the rate of successful therapies has im-
proved continuously over recent years [4]. Therefore, a
viral load below the detection limit is currently one of
the cornerstones of patient management. As long as
eradication of HIV infection is not achievable, HAART
still has to be applied continuously for the lifetime of the
patient.
The essential determinants of sustained inhibition of
viral replication are: potency of applied drugs, immuno-
logical host factors, resistance of the virus, and patient
aspects such as feasibility of the drug combination as
well as adherence [5]. Little is known about the associ-
ation of medical care setting for treatment success.
There is, for example, data on cost-effectiveness of HIV
care in private practices versus public hospitals in South
Africa [6]. Another study from Switzerland focused on
the improvement of co-operation between different facil-
ity types [7]. To our knowledge, there are, to date, no
outcome results relevant for medical prognosis of pa-
tients considering medical care setting.
In this study, we present data on epidemiological char-
acteristics and treatment outcome of HIV-infected pa-
tients considering medical facility type in Germany. The
structure of HIV care in Germany is diverse. In the am-
bulatory setting, numerous medical practices as well as
hospital-based units offer care for HIV-infected patients,
with free access to each type according to patients’
wishes. Quality assurance regulations ensure a high
standard of medical management.
The present analysis was extracted from the RESINA
study, a prospective cohort of HIV-infected patients after
initiation of HAART.
Methods
The RESINA study is an ongoing prospective multicen-
ter investigation on the epidemiology of transmitted
drug resistance in chronically HIV-infected patients
in Nordrhein-Westfalen, the largest federal state of
Germany by population [8]. Since 2001, more than 2,500
patients were recruited in 36 centers (see Appendix).
Follow-up after initiation of first-line HAART is being
performed in a longitudinal cohort. All centers arespecialized in HIV care. The dataset served for the devel-
opment of treatment outcome prediction tools using
bioinformatic analyses of complex mutational patterns [9].
The RESINA study is part of the nationwide project
‘Monitoring of resistant HIV in newly infected and chron-
ically infected patients in Germany’, with collaboration
from the Robert Koch Institute, the Paul-Ehrlich-Institute,
and the RESINA study group. Further co-operation with
European multicenter projects such as the EuResist
Network and the Collaborative HIV and Anti-HIV Drug
Resistance Network (CHAIN) are being implemented.
The present analysis covers patients who were included
in the study between 2001 and 2009, with available follow-
up data to at least 48 weeks and end of 2010. Inclusion
criteria of the study were: documented HIV-1 infection
and the decision of physician and patient on the initiation
of first-line HAART, indicated by virological, immuno-
logical, or clinical aspects. Exclusion criteria were: previ-
ous application of antiretrovirals and non-willingness to
participate. All relevant institutional review boards of co-
operating centers rendered positive approval.
Genotypic resistance testing and interpretation of
results was applied using geno2pheno (Max Planck Insti-
tute for Informatics, Saarbrücken, Germany) as previ-
ously described [10]. For test interpretation, the current
World Health Organization (WHO) mutation list for the
classification of primary or transmitted drug resistance
was additionally used to provide clinically relevant ad-
vice [11]. Each doctor had a test result available for the
treatment choice.
The whole study population was divided into patients
treated in outpatient hospital units and patients treated
in medical practices. Recruitment into the RESINA
study was relevant for inclusion; subsequent movements of
the patients between the institutions were not recorded.
The following baseline parameters were determined:
gender, age, nationality, ethnic origin, HIV transmission
group, time since determination of positive HIV test,
clinical state using CDC stage, CD4 cell count, HIV load,
HIV-1 subtype, and primary drug resistance. The applied
regimens were divided into treatment combination
types. Treatment outcome was measured by the rate of
patients with a viral load below the limit of detection
(50 copies/mL) and median amount of CD4 cell count at
the time points of 24, 48, 72, and 96 weeks.
For the statistical analysis SPSS version 19 (IBM,
Armonk, NY, USA) was used. Univariate comparisons
were performed with Wilcoxon rank-sum test or Fisher’s
exact test, as appropriate. A p-value of ≤0.05 was
regarded as significant; adjustment for multiple testing
was not applied. Covariate influence on therapy success
as demonstrated by the risk of viral failure after 48 weeks
was examined by multivariate analysis using logistical
regression. A model considering items with significant
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known impact on treatment outcome was fitted to the
data. The parameters of treatment facility, baseline CDC
stage and HIV load, transmitted drug resistance, and
HIV-1 subtype were included.Table 1 Baseline characteristics of the cohort
Parameter Total Private pr











Other (<2%) 18.6 13.3





Other (<1%) 1.6 1.7
Missing data 0.4 0.6
HIV transmission groups (%)
MSM 52.5 68.3
Heterosexual 18.7 12.2
Endemic region 14.6 7.3
Intravenous drug abuse 5.7 5.3
Others (<1%) 1.6 0.4
Missing data 6.9 6.5
Duration of HIV-positivity
(months) (median, range)





CD4 cell count (CD4 cells/μL)
(median, range)
210 (0 to 1,224) 246.5 (0 to
Viral load (copies/mL)
(median, range)
75,345.5 (227 to 5,022,690) 100,000 (227 to




Values presented as percentages, unless otherwise indicated. CDC, Centers for DiseResults
The treatment centers cooperating in the study con-
sisted of four outpatient units of university clinics, four
outpatient units of communal hospitals, and 28 medical





69) 38 (18 to 78) 0.1





















260) 1 (0 to 244) <0.001




1,224) 189.5 (1 to 1,014) <0.001
5,022,690) 68,828 (508 to 500,000) 0.041
67.7 <0.001 (B versus others)
9.2 0.36 (resistance versus wild type)
ase Control and Prevention; MSM, men who have sex with men.
Figure 2 Immunological outcome of therapy. Median CD4 cell
count (CD4 cells/μL).
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period from 2001 to 2009. Of these, 1,099 were treated
in hospital-based units and 492 in private practices. The
baseline characteristics of the population are demon-
strated in Table 1. Significant differences in the distribu-
tion among the treatment settings were found for
gender, nationality, ethnic origin, HIV transmission
group, duration of HIV-positivity, CDC stage, CD4 cell
count, viral load, and HIV-1 subtype.
Overall, 90.3% of patients had standard combinations
as defined by European or German-Austrian guidelines.
Of these, 49.0% of patients had a combination with two
nucleoside reverse transcriptase inhibitors (NRTIs) and a
ritonavir-boosted protease inhibitor (PI); 37.4% received
a combination of two NRTIs with a non-nucleoside
reverse transcriptase inhibitor. For 3.9% of patients, a
single PI was combined with two NRTIs. A subset of pa-
tients had other combinations (for example more than
three active drugs in the regimen (3.6%) in special situa-
tions such as transmitted drug resistance).
Figure 1 shows the rate of patients with effective ther-
apy, as measured by a viral load below the level of
detection. For 81.9% (hospital-based units) and 85.9%
(medical practices) of patients with a suppressed viral
load after 48 weeks there was no significant difference
between the different treatment settings (p = 0.12). Cor-
responding values at 96 weeks were 86.0% versus 87.6%
(p = 0.54). The development of the CD4 cell count is
demonstrated in Figure 2. Despite the different values at
baseline and at the follow-up time points (p <0.001 for
all comparisons), the two graphs show parallel develop-
ment with a median increase of 235.5 CD4 cells/μL in
hospital-based units and 231.5 CD4 cells/μL in private
practices (p = 0.62), respectively.
The result of the multivariate analysis is shown in
Table 2. Considering the rate of patients with detectable
viral load after 48 weeks, only the HIV-specific baseline
parameter CDC stage (AIDS versus non-AIDS) was
found to have significant impact on therapy efficacy afterFigure 1 Virological outcome of therapy. Rate of patients with a
viral load <50 copies/mL.adjustment of the items: treatment setting, viral load,
transmitted drug resistance, and HIV-1 subtype.
Discussion
The RESINA study is a prospective multicenter trial of
HIV therapy in Nordrhein-Westfalen, Germany, which
has been running since 2001 [8]. Due to the similarity of
the study cohort and the HIV-infected population in
Germany [10,12], the inclusion criteria of intended initi-
ation of first-line HAART and the recruitment of more
than 1,500 patients, the data may represent current treat-
ment reality of HIV-positive patients. The aim of the in-
vestigation was to analyze epidemiological features and
treatment outcome results of first-line HAART with re-
gard to patients’ medical care setting. As discussed above,
there is no evidence regarding this topic existing to date.
In this study, we found significant differences between
the baseline parameters of HIV-infected patients cared
for in hospital-based outpatient units and private prac-
tices. Patients in hospital-associated settings showed a
higher proportion of CDC stage of AIDS, a lower CD4
cell count, and a higher frequency of non-B HIV-1 sub-
type. Patients who presented to medical practices of gen-
eral practitioners or infectious disease specialists were
predominantly Caucasian men who have sex with men
(MSM) of German nationality. Thus, in Germany,
the HIV population in ambulatory care is distributed
heterogeneously regarding medical facility types. Al-
though the median viral load differed significantly in
both groups, we consider the amount of approximately
30,000 copies/mL to be clinically not relevant. This is
confirmed by the multivariate analysis, which shows that
baseline viral load had no significant impact on therapy
outcome. However, the characteristics suggest unequal
chances of efficient antiretroviral therapy due to the in-
ferior clinical stage of patients in hospital-based units.
Despite different distribution of baseline predictors of
successful HAART, treatment efficacy was comparable
in the two groups. The rate of study participants with a
viral load below the level of detection was very similar in
Table 2 Multivariate analysis considering treatment efficacy
Parameter OR 95% CI P value
Treatment setting: hospital versus private practice 0.94 0.53 to 1.68 0.85
CDC stage: AIDS versus non-AIDS 1.82 1.09 to 3.06 0.023
HIV load: for each log c/mL 1.2 0.82 to 1.75 0.34
Transmitted drug resistance: resistance demonstrated versus wild type virus 0.81 0.33 to 2.0 0.65
HIV-1 subtype: B versus others 0.72 0.42 to 1.25 0.55
Risk of viral failure (viral load >50 copies/mL) after 48 weeks. CDC, Centers for Disease Control and Prevention; CI, confidence interval; OR, adjusted odds ratio.
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above 80% after 48 weeks and 85% after 96 weeks in the
two strata, and no significant difference at both time
points. The CD4 cell count was significantly different at
baseline, but the increase after initiation of HAART was
almost identical in both groups up to 96 weeks. At the
end of follow-up, the median CD4 cell count was well
above 400/μL in the two populations. Further evaluation
of the data using multivariate analysis could not show an
association of treatment setting with virological outcome
at 48 weeks after adjustment for baseline viral load, trans-
mitted drug resistance, and HIV-1 subtype. Only baseline
CDC stage (AIDS versus non-AIDS) was associated with
treatment success, a fact that is well-known from clinical
practice. As previously demonstrated [13], transmitted
drug resistance was not associated with inferior outcome.
This is due to the fact that the cases presenting with viral
mutations received a combination therapy optimized by
resistance test results. In summary, overall virological and
immunological efficacy of first-line HAART was very
good, independent of medical care facility.
The higher rate of individuals of non-Caucasian ethnic
origin and non-European nationality treated in hospital-
based units was accompanied by a higher rate of the het-
erosexual transmission group and a lower rate of non-B
HIV-1 subtype. However, the lower proportion of these
patients in private practices compared to German pa-
tients with a predominantly MSM-transmission group
remains to be interpreted. It may be speculated that ac-
cess to outpatient units is easier for migrants from out-
side Europe compared to access to medical practices.
Another observation was that patients in hospital-based
units showed an inferior clinical CDC stage. A possible
explanation is that patients with reduced medical condi-
tions need hospital inpatient care more often and there-
fore may stay at the hospital’s outpatient unit for further
therapy.
The outcome data suggest that disparities between the
baseline characteristics of the patient strata in the differ-
ent medical care facilities do not influence the good
overall efficacy of HAART. This may be due to the wide-
spread availability of potent drug combinations, the con-
sideration of baseline resistance testing, the high level of
medical expertise of the treating physicians, or goodpatient adherence. These parameters seem to be more
important than medical facility type. Whether these
findings can be translated into other countries’ settings
is unclear. They show, however, that current antiretro-
viral treatment in Germany is very successful, independ-
ent of other circumstances.
Several limitations of the results should be considered.
The large number of cooperating centers and the long
period of the study may lead to heterogeneity of
methods and applied therapy combinations. This may
also be induced by a change of therapeutic concepts and
introduction of new antiretroviral compounds during
the study period. Furthermore, due to the realization of
the study in clinical practice, treatment modifications
and patient fluctuations from one medical unit to the
other are not included in the analysis. However, consid-
ering all study centers were specialized in HIV medicine,
the large number of included patients treated in the geo-
graphic region of the study [10,12], and the continuously
applied study protocol, the limitations may be regarded
as limited and the results as valid. For proof of the find-
ings, a prospective randomized trial on the topic is ne-
cessary. However, in the authors’ opinion, it is very
unlikely that a study with this design would be feasible
or find adequate funding. Therefore, the results of this
prospective cohort provide the best evidence to date to
support the assumption that antiretroviral therapy effi-
cacy is comparable in the two types of medical facilities.
Conclusion
In summary, the present analysis of the prospective mul-
ticenter RESINA study shows that for more than 1,500
patients first-line antiretroviral therapy is very effective
for the vast majority of patients independent of medical
care setting. This positive finding is even more valid as
patient populations differ significantly in baseline param-
eters relevant for treatment outcome in hospital-based
units compared to private practices.
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Cooperating centers in Germany
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